New drug could keep leukemia from returning after transplant

NCT ID NCT06707493

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 22 times

Summary

This study tests whether a daily pill called ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It is for people with a specific IDH1 gene mutation. About 75 participants will receive either ivosidenib or a placebo to see if the drug improves relapse-free survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Froedtert Hospital & the Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.